Cempra to Receive BARDA Funding for 1b and Start-Up of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies

$16.0 Million Will be Provided to Cover the Cost of the Study and Other Activities Specified in the Contract

Phase 1b and Phase 2/3 Studies Will Test Intravenous, Oral Capsule and Oral Suspension Formulations of Solithromycin in Pediatric Patients From Newborn to 17 Years of Age

CHAPEL HILL, N.C., Nov. 19, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP ), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it has received authorization under its existing contract for the next phase of its contract with the Biomedical Advanced Research and Development Authority ( BARDA ) that will provide funding of $16.0 million for two clinical studies of solithromycin. Pediatric patients from newborn to age 17 years who are enrolled in the study may receive intravenous, oral suspension or oral capsule formulations of solithromycin, an investigational, fourth generation macrolide antibiotic. In a recently completed Phase 1a study conducted in pediatric patients age 12 to 17 years, solithromycin oral capsules were well tolerated and demonstrated a pharmacokinetic profile similar to that seen in adults.

"I am pleased with the progress we are making under our continuing collaborative and constructive BARDA relationship that has resulted in the approval of funding for the next phase of our investigational studies with solithromycin in pediatric patients that is expected to extend our indications," stated Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra. "BARDA's continuing recognition of the potential of solithromycin to have broad utility in all age groups allows our pediatric program to run in parallel with our adult Phase 3 studies in adults with community acquired bacterial pneumonia and in uncomplicated gonorrhea."

Initial funding from BARDA of $17.7 million supported the Phase 1a clinical study that enrolled pediatric patients between the ages of 12 to 17 years with suspected or confirmed bacterial infections. Each patient received solithromycin oral capsules for up to five days as add-on therapy in addition to standard of care treatments for a variety of infections, including sinusitis, exacerbations of cystic fibrosis as well as skin and soft tissue infections. Pharmacokinetics of the oral capsules in this age group were comparable to data from adult studies of solithromycin and it was well tolerated. Cempra has also reported positive results in treating tularemia and anthrax in non-clinical models which was also funded by BARDA in the first year of the contract.

The Phase 1b portion of the study will enroll up to 64 pediatric patients aged newborn to 17 years with suspected or confirmed bacterial infections. Patients will receive oral capsules, oral suspension or intravenous solithromycin dosed by weight once per day as add on therapy for up to 5 days. The study is open label and the primary endpoint will be to determine pharmacokinetics in the pediatric population. Safety data will also be collected. For additional information about this Phase 1b study please visit clinicaltrials.gov . On-going with this program, as part of this funding is the optimization of the commercial pediatric suspension product and we are expected to begin the start-up activities for a global Phase 2/3 study.

About the Cempra BARDA Agreement

In May 2013, Cempra entered into a five year agreement with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (Contract No. HHS0100201300009C) for the evaluation and development of solithromycin for the treatment of bacterial infections in pediatric populations and infections caused by bioterror threat pathogens, specifically anthrax and tularemia. The BARDA agreement is a cost plus fixed fee development contract with a base performance segment plus four option segments. If all four option segments are requested, the total value of the agreement would be approximately $58.6 million with a period of service to 2018.

About Cempra, Inc.

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in Phase 3 clinical development for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin also recently entered a Phase 3 clinical trial for uncomplicated bacterial urethritis caused by Neisseria gonorrhoeae and chlamydia. Taksta™ (CEM-102) is Cempra's second product candidate, which is being developed for chronic oral treatment of staphylococcal infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com .

Please Note : This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the costs, timing, regulatory review and results of our studies and clinical trials and those of our strategic commercial partners; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our anticipated capital expenditures and our estimates regarding our capital requirements; our and our strategic commercial partners' ability to obtain FDA and foreign regulatory approval of our product candidates; the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties; the unpredictability of the size of the markets for, and market acceptance of, any of our products, including solithromycin and Taksta; our ability to produce and sell any approved products and the price we are able to realize for those products; our ability to retain and hire necessary employees and to staff our operations appropriately; our ability to compete in our industry; our dependence on the success of solithromycin and Taksta; innovation by our competitors; and our ability to stay abreast of and comply with new or modified laws and regulations that currently apply or become applicable to our business. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.

Mark W. Hahn Chief Financial Officer (919)-313-6601 Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 Media Contacts: Russo Partners, LLC Robert E. Flamm, Ph.D. (212) 845-4226 Lena Evans (212) 845-4262

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 25

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 142

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 115

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 150

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 81

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 177

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 98

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 115

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 83

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 96

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading

Top 5 Most Recently Viewed Articles

New Terminal One Partners with Plaza Premium to Elevate Travel

Updated Category News Views 234

New Terminal One & Plaza Premium Group Collaboration The New Terminal One at JFK International Airport has joined forces with Plaza Premium Group (PPG), a leading name in airport hospitality, to create two state-of-the-art lounges. Together, they aim to transform the travel experience at this vital international hub, covering close to 14,000 square feet and promising...

Continue Reading
Market Update: S&P 500 Fluctuates After Holiday Trading

Updated Category News Views 337

S&P 500 Experiences Mixed Results in Light Trading The recent trading session saw the S&P 500 close on a flat note after a day of ups and downs, all in the backdrop of lower-than-usual trading volumes, a trend typical of the holiday breakout. As of the market close, the S&P 500 had dipped by 0.1%, while the NASDAQ Composite mirrored this decrease. In contrast, the Dow...

Continue Reading
Brand Engagement Network Expands Horizons with Cataneo Acquisition

Updated Category News Views 104

Brand Engagement Network Expands Strategic Capabilities Jackson, Wyo. – brand Engagement Network, Inc. (NASDAQ: BNAI) has recently made headlines by agreeing to acquire a German media technology powerhouse, Cataneo Gmbh. This acquisition not only highlights BEN's commitment to growth but also demonstrates its ambition to transform how brands use AI to engage with their...

Continue Reading
Metagenomi Showcases Advanced Adenine Base Editors for Gene Therapy

Updated Category News Views 195

Introducing Metagenomi's Innovative Adenine Base Editors Metagenomi has unveiled its cutting-edge Adenine Base Editors (ABEs) at a recent event, highlighting their impressive capabilities in genome editing. These novel tools achieved over 95% targetability in gene modification, demonstrating exceptional performance and efficiency. Key Highlights from the Presentation...

Continue Reading
Streamlining IT Procurement: SysAid Launches on AWS Marketplace

Updated Category News Views 49

SysAid Now Accessible via AWS Marketplace SysAid, a leading Enterprise and IT Service Management solution provider, has made an exciting announcement regarding its availability on AWS Marketplace. This curated digital catalog is designed to simplify the process of discovering, procuring, and deploying software solutions. With AWS Marketplace having over 290,000 active...

Continue Reading